Sichuan Biokin Pharmaceutical (SHA:688506) posted first-half attributable net loss of 1.64 billion yuan, compared with a loss of 1.13 billion yuan the previous year.
Loss per share widened to 3.97 yuan from 2.79 yuan, according to a Thursday filing with the Shanghai bourse.
Operating revenue rose 9.4% year over year to 187.3 million yuan from 171.2 million yuan.
Shares of the pharmaceutical company declined 2% in recent trade.